Understand the source comparison
Stop Taking PE-22-28: Discontinuation Protocol Comparison
Abrupt cessation (no taper) 10–14 days to undetectable plasma levels High. 7–10 day hypersensitivity window post-cessation Moderate. Expect variability spike in Days 4–14 post-dose Short-duration studies (≤3 weeks) where receptor adaptation is minimal Acceptab
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Abrupt cessation (no taper)
- 10–14 days to undetectable plasma levels
- High. 7–10 day hypersensitivity window post-cessation
- Moderate. Expect variability spike in Days 4–14 post-dose
- Short-duration studies (≤3 weeks) where receptor adaptation is minimal
- Acceptable for brief protocols; avoid for CNS-targeted studies ≥4 weeks
- 7-day taper (50% reduction final week)
- 12–16 days to full clearance
- Moderate. 4–5 day rebound window
- Good. Reduced post-treatment variability
- Standard approach for 4–8 week protocols
- Recommended default for most research applications
- 14-day taper (gradual step-down)
- 14–18 days to full clearance
- Low. Minimal rebound, gradual receptor normalization
- Excellent. Tightest confidence intervals at endpoint
- Long-duration studies (≥8 weeks) or high-dose regimens
- Gold standard for rigorous CNS or metabolic studies
- Immediate transition to alternative peptide (no washout)
- Overlapping plasma levels for 10–14 days
- Variable. Depends on receptor cross-reactivity
- Poor. Confounded attribution of effects
- Not recommended unless receptor mechanisms are entirely distinct
- High risk of interpretive error; use only with clear mechanistic separation
- Extended washout (21+ days post-final-dose before endpoint measurement)
- Full clearance verified by LC-MS
- None. Receptors return to pre-treatment baseline
- Excellent. Cleanest post-treatment data
- Studies requiring true baseline restoration or sequential compound testing
- Required for comparative efficacy studies and crossover designs
- This comparison table reflects observed outcomes across preclinical neurotrophin peptide research. The 'Best Use Case' column assumes standard subcutaneous dosing regimens and CNS-targeted endpoints—adjust washout timelines for hepatic or renal function studies where clearance kinetics differ.